<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04984993</url>
  </required_header>
  <id_info>
    <org_study_id>FM71</org_study_id>
    <nct_id>NCT04984993</nct_id>
  </id_info>
  <brief_title>Clinical Investigation Using MED3000 Gel or Tadalafil Tablets in the Treatment of Erectile Dysfunction</brief_title>
  <official_title>A Multi-centre, Randomised, Open-label, Home Use, Parallel Group, Clinical Investigation of Topically-applied MED3000 Gel and Oral Tadalafil (5 mg) Tablets for the Treatment of Erectile Dysfunction (ED) Over a 24 Week Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Futura Medical Developments Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Futura Medical Developments Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label investigation using MED3000 gel or tadalafil (5 mg) tablets in the treatment of&#xD;
      erectile dysfunction in patients from 22 to 70 years of age. Each patients will be expected&#xD;
      to participate for up to 30 weeks. Eligible patients will be randomised to receive either&#xD;
      MED3000 gel or tadalafil (5 mg) tablets in a 1:1 ratio.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomised to receive either MED3000 gel or tadalafil (5 mg) tablets after a 4 -6 week screening period</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in EF in patients receiving MED3000 gel</measure>
    <time_frame>24 weeks</time_frame>
    <description>Demonstrate an improvement of erectile function in patients randomised to receive MED3000 using the IIEF-EF patient reported out outcome instrument.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change of EF from baseline score (Rosen et al 2011)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Observe a mean change from baseline (IIEF-EF) is greater or equal to the minimal clinically importance difference as published in Rosen et al 2011</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Onset of Action speed of MED3000 (onset of erection)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Demonstrate a speed of onset of action from application of MED3000 gel to the time when patient notices their erection starting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Onset of Action speed of MED3000 (penetrative sex)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Demonstrate a speed of onset of action from application of MED3000 gel to the time when the patients is able to have penetrative sex.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Difference from baseline scores (MED3000 and tadalafil)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Estimate a difference between MED3000 and tadalafil in improvement compared to baseline of IIEF-EF</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean change in IIEF- EF from baseline scores</measure>
    <time_frame>20 weeks</time_frame>
    <description>Evaluate the mean change from baseline (IIEF-EF) at Weeks 4, 8, 12, 16 and 20 post-randomisation</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of patients reporting improvement in IIEF-EF scores as per Rosen et al 2011</measure>
    <time_frame>24 weeks</time_frame>
    <description>Evaluate the proportion of patients reporting a meaningful improvement in IIEF-EF scores according to the criteria published by Rosen et al 2011</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean score change in questions 3 and 4 in IIEF</measure>
    <time_frame>24 weeks</time_frame>
    <description>Evaluate the mean change from baseline scores in questions 3, and 4 of the IIEF assessed at every 4 weeks after randomisation</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean change in baseline score (other IIEF domains)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Evaluate the mean change from baseline of other IIEF domains assessed every 4 weeks after randomisation</description>
  </other_outcome>
  <other_outcome>
    <measure>SEAR evaluaiton</measure>
    <time_frame>24 weeks</time_frame>
    <description>Evaluate the sexual intercourse experience using the Self-Esteem And Relationship questionnaire.</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety</measure>
    <time_frame>24 weeks</time_frame>
    <description>Evaluate the safety of MED3000 and tadalafil using the occurence and severity of treatment-emergent adverse events and standard physical and laboratory assessments.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>MED3000</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MED3000 gel formulation topically applied to the glans penis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tadalafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tadalafil (5 mg) tablets to be taken orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MED3000</intervention_name>
    <description>Gel formulation</description>
    <arm_group_label>MED3000</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tadalafil 5mg</intervention_name>
    <description>Tablets</description>
    <arm_group_label>Tadalafil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male heterosexual patients aged 22-70 years.&#xD;
&#xD;
          -  Confirmed clinical diagnosis of mild, moderate or severe ED for more than 3 months.&#xD;
&#xD;
          -  Involved in a continuous heterosexual relationship with their partner for at least 6&#xD;
             months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal,&#xD;
             haematological, endocrinological, metabolic, neurological or psychiatric disease.&#xD;
&#xD;
          -  History of unstable medical or psychiatric condition or using any medication that, in&#xD;
             the opinion of the Principal Investigator, is likely to affect the patient's ability&#xD;
             to complete the investigation or precludes the patient's participation in the&#xD;
             investigation.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Male patients who have had erectile dysfunction for at least 3 months</gender_description>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andrew Graham, BSc (Hons)</last_name>
    <phone>+44 7969 759926</phone>
    <email>andy.graham@futuramedical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tim Holland, MBA</last_name>
    <phone>+44 7803 007764</phone>
    <email>tim.holland@futuramedical.com</email>
  </overall_contact_backup>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 26, 2021</study_first_submitted>
  <study_first_submitted_qc>July 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2021</study_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tadalafil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

